Filing Details
- Accession Number:
- 0001104659-24-106797
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-10-07 20:51:11
- Reporting Period:
- 2024-10-07
- Accepted Time:
- 2024-10-07 20:51:11
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1727196 | Scholar Rock Holding Corp | SRRK | Biological Products, (No Disgnostic Substances) (2836) | 823750435 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1834528 | L. Jing Marantz | 301 Binney Street Cambridge MA 02142 | Chief Medical Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2024-10-07 | 109,375 | $8.59 | 182,230 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2024-10-07 | 67,448 | $25.59 | 114,782 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-10-07 | 2,552 | $26.22 | 112,230 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-10-07 | 39,375 | $30.06 | 72,855 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2024-10-07 | 109,375 | $0.00 | 109,375 | $8.59 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 140,625 | 2032-11-14 | No | 4 | M | Direct |
Footnotes
- These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on April 19, 2024.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.15 to $26.12, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.20 to $26.335, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.44, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
- Options vest over four years with 25% vesting on November 9, 2023 and the remainder vesting in 12 quarterly installments thereafter, provided the reporting person continues to have a service relationship with the Issuer as of the applicable vesting date.
Billionaire Hedge Funds
